Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 161Tb-LNC1011.
- Who it may be relevant to
- Registry conditions: Prostate Cancer. Basic parameters: from 18 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Prospective, Open-label, Dose-Escalation, Single-Center Study to Evaluate the Safety, Biodistribution/Dosimetry and Preliminary Efficacy of 161Tb-LNC1011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Overview
This is a prospective, open-label, single-center, dose-escalation study using a standard 3+3 design to assess the safety, tolerability, biodistribution/dosimetry and preliminary efficacy of the albumin-binding PSMA radioligand 161Tb-LNC1011 in patients with metastatic castration-resistant prostate cancer (mCRPC). Patients will receive intravenous 161Tb-LNC1011 starting at 50 mCi with planned dose-level escalations to 80, 130 and 200 mCi (±10%). Early dose levels (50 mCi) receive 1 cycle; later levels receive up to 4 cycles every 6 weeks based on safety and disease status. Primary endpoints include dose-limiting toxicities (DLTs), adverse events (AEs) graded by CTCAE v5.0, and determination of maximum tolerated dose (MTD). Secondary endpoints include organ/tumor absorbed doses, PSA responses (PSA50/PSA90), disease control, time to PSA progression and radiographic progression-free survival per PCWG3.
Detailed description
Rationale: 161Tb emits β-particles plus abundant low-energy conversion/Auger electrons (very short range, high LET), potentially improving tumoricidal effect-especially for micrometastases-vs 177Lu. LNC1011 is a PSMA ligand with albumin-binding moiety designed to prolong circulation and enhance tumor uptake/retention. Preclinical and early clinical data support feasibility and safety.
Design: 3+3 dose-escalation. Dose levels (activity to be administered IV): 50 mCi (45-55), 80 mCi (72-88), 130 mCi (117-143), 200 mCi (180-220). DLT window: 6 weeks post-dose. If ≥2/6 DLTs, de-escalate; the prior dose is MTD.
Dosing/Cycles: Early dose level (50 mCi) one cycle; later levels up to 4 cycles q6 weeks. Retreatment contingent on hematologic recovery to CTCAE Grade ≤1 or baseline.
Imaging \& Dosimetry: Post-dose SPECT/CT at \~30 min, 2 h, 8 h, 24 h, Day 2, Day 7 for time-activity curves and dosimetry. Disease assessments with 68Ga-PSMA-11 PET/CT and labs (PSA, hematology, chemistry) per schedule.
Safety Monitoring: Continuous AE/SAE recording from consent through 28 days post-last dose (or longer if related), DMC oversight (see below).
Interventions
- Drug 161Tb-LNC1011
Intravenous administration; planned dose levels: 50, 80, 130, 200 mCi (±10%); cycle interval q6 weeks; up to 1 cycle at 50 mCi and up to 4 cycles at later dose levels as permitted by safety and disease status.
Primary outcome measures
- Incidence of Dose-Limiting Toxicities (DLTs) [Time frame: First 6 weeks after each initial dose at a given dose level]
- Maximum Tolerated Dose (MTD) [Time frame: At completion of dose escalation (approximately 12-18 months after study start)]
- Treatment-Emergent Adverse Events (TEAEs) [Time frame: From first dose through 28 days after last dose (extended if related)]
Secondary outcome measures (2)
- Organ and Tumor Absorbed Doses (Dosimetry) [Time frame: Within first cycle (Day 0 to Day 7 imaging)]
- PSA50 and PSA90 Response Rates [Time frame: Every 6 weeks during treatment and at end of treatment (up to approximately 24 weeks)]
Eligibility criteria
Inclusion criteria
- Male, ≥18 years.
- Pathologically confirmed mCRPC per PCWG3.
- 68Ga-PSMA-11 PET/CT positive.
- Prior exposure to at least one novel androgen-axis drug (e.g., enzalutamide and/or abiraterone) or at least one taxane regimen, or intolerance/refusal to taxane chemotherapy.
- ECOG 0-2; life expectancy ≥6 months.
- Adequate organ function: ALT/AST ≤3× ULN; BUN/Cr ≤1.5× ULN; WBC ≥3.5×10\^9/L; PLT ≥100×10\^9/L; Hb ≥90 g/L.
- Signed informed consent and willingness to comply with study procedures.
Exclusion criteria
- Major trauma/surgery within 4 weeks prior to study treatment.
- Active severe systemic or localized infection or other serious comorbidity.
- Immunodeficiency or recent use of immunosuppressants/immunoenhancers, recent vaccines.
- Autoimmune diseases (e.g., rheumatoid arthritis) requiring active management.
- Uncontrolled arrhythmias (incl. Afib), heart failure NYHA > II, uncontrolled hypertension.
- Known allergy to components of investigational product.
- Positive syphilis, HBV/HCV/HIV.
- Inadequate contraception in patients of reproductive potential.
- Psychiatric illness compromising compliance.
- Unable to undergo SPECT/CT or to retain urine for 30 minutes.
- Any condition deemed unsuitable by the investigator.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 2 centers
- Peking Union Medical College Hospital — Beijing
- Mianyang Central Hospital — Mianyang
Identifiers
NCT: NCT07381582 · PUMCH-MCH-161Tb-LNC1011